ToxSci Advance Access originally published online on May 21, 2007
Toxicological Sciences 2007 98(2):436-444; doi:10.1093/toxsci/kfm125
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A Proposed Mechanism for the Protective Effect of Dioxin against Breast Cancer
,2,3,1
* Molecular Toxicology Interdepartmental Doctoral Program, School of Public Health
Department of Pathology and Laboratory Medicine and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California
1 To whom correspondence should be addressed at Department of Pathology and Laboratory Medicine, Box 951732 Center for Health Sciences, University of California Los Angeles, Los Angeles, CA 90095-1732. Fax: (310) 794-9272. E-mail: ohank{at}mednet.ucla.edu.
Received March 21, 2007; accepted May 14, 2007
 |
Abstract |
|---|
Although it is causative for many types of cancers, experimental and epidemiological evidence suggest that 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin) may in fact protect against breast cancer. The mechanism(s) for this protection remain unclear. In an attempt to further elucidate this mechanism, we performed a microarray experiment to identify genes that were modulated upon dioxin treatment. We found that dioxin downregulated the messenger RNAs for the G-protein–coupled receptor, CXCR4, as well as its unique chemokine ligand, CXCL12, in MCF-7 breast cancer cells. We demonstrated that the corresponding proteins are also downregulated by dioxin. The interaction between CXCR4 and CXCL12 plays a central role in the metastasis of breast cancer, as disruption of the CXCL12/CXCR4 axis has been shown to limit the metastasis of breast cancer cells to the lung in mice. Utilizing an in vitro chemotaxis assay, we demonstrate that dioxin specifically inhibits the migration of MCF-7 cells toward CXCL12. We also show that dioxin reduces CXCR4 under hypoxia and CXCL12 under estradiol-induced conditions in MCF-7 cells. Finally, as the CXCR4/CXCL12 axis is implicated in the progression of numerous types of cancer, we identified several other cancer cell lines in which dioxin modulates CXCR4 and CXCL12 levels. We therefore propose that one mechanism whereby dioxin may protect against breast cancer is via downregulation of CXCR4 and CXCL12, thereby inhibiting progression of the disease. Further, other nontoxic ligands for the aryl hydrocarbon receptor (selective AHR modulators) may exert their protective effects by a similar mechanism.
Key Words: dioxin; CXCR4; CXCL12; breast cancer; AHR; chemokine receptor.
2 Current address: 6 Paddock Lane, Great Neck, New York 11020.
3 Current address: UT M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 0432, Houston, Texas 77030.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. R. Beedanagari, I. Bebenek, P. Bui, and O. Hankinson Resveratrol Inhibits Dioxin-Induced Expression of Human CYP1A1 and CYP1B1 by Inhibiting Recruitment of the Aryl Hydrocarbon Receptor Complex and RNA Polymerase II to the Regulatory Regions of the Corresponding Genes Toxicol. Sci., July 1, 2009; 110(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Singh, A. Wyman, F. L. Casado, R. W. Garrett, and T. A. Gasiewicz Treatment of mice with the Ah receptor agonist and human carcinogen dioxin results in altered numbers and function of hematopoietic stem cells Carcinogenesis, January 1, 2009; 30(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Taylor, F. Wang, E. L. Hsu, and O. Hankinson Roles of Coactivator Proteins in Dioxin Induction of CYP1A1 and CYP1B1 in Human Breast Cancer Cells Toxicol. Sci., January 1, 2009; 107(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|